Sobrevida de pacientes com câncer de mama submetidas à quimioterapia adjuvante nos serviços de oncologia em Juiz de Fora, Minas Gerais
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
This study, undertaken in the city of Juiz de Fora, Minas Gerais, Brazil, analyzed
the 5-year survival rate of 428 women, after they were diagnosed with invasive
breast cancer. The subjects were diagnosed between January 1998 and
December 2000, and underwent curative surgery and adjuvant chemotherapy.
The patients were enrolled from all the oncology services of the
municipality, and followed up until December 2005. Survival time was assessed
from the date the histopathological diagnosis was made. The date the patient
died of breast cancer was considered a failure. The women alive until the final
follow-up date (31/12/2005) were censored. For those confirmed as losses,
censor date was the one of the last entry in the medical file. The main variables
analyzed were: age at diagnosis, race, tumor size, number of lymphnodes
involved, clinical stage, and chemotherapy regimen. Kaplan-Meier survival curves
were obtained, with the differences assessed by the log-rank test. For
assessment of prognostic factors, hazard ratios (HR) with the corresponding 95%
confidence intervals were obtained through an adjusted Cox proportional hazards
model.
Mean age was 51.2 years (range 25-81), and most (72.6%) were white.
Clinical stages II (47.4%) and III (38.6%) predominated. An anthracyclic-based
chemotherapy regimen was used in 56.1%. Breast cancer five-year survival rate
was 82.0%. Survival was significantly shorter in women diagnosed before
menopause (p=0.02), with tumor size greater than 2cm (p=0.05), with lymphnode
involvement (p=0.000), with more advanced disease stage (p=0.000), and in
those with full adjuvant chemotherapy regimen (p=0.03). The number of
lymphnodes involved and hormone use were the most important prognostic
xiv 14
factors independently associated with survival in the study population, with greater
death risk for those with more than 10 lymphnodes involved (HR=7.30, 95%CI:
3.15-16.88) and for those who did not receive hormone therapy (HR=2.04; 95%CI:
1.24-3.37). The results highlight the importance of early diagnosis and treatment, so that better survival rates may be achieved.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
Acesso Aberto
